From Nasdaq.: 2025-03-31 02:27:00

AstraZeneca’s Imfinzi, in combination with gemcitabine and cisplatin, approved in the US for treating muscle-invasive bladder cancer after surgery. FDA approval based on NIAGARA Phase III trial results, showing 32% reduced risk of recurrence and 25% reduced risk of death compared to chemotherapy alone. Imfinzi also approved in Brazil, with regulatory applications under review in EU, Japan, and other countries. (RTTNews)



Read more at Nasdaq.: AstraZeneca’s Imfinzi Combo Approved In US For Muscle-Invasive Bladder Cancer Treatment